Oxford Biomedica (LON:OXB) Issues Quarterly Earnings Results

Oxford Biomedica (LON:OXB) posted its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%.

Oxford Biomedica Trading Up 1.8%

Shares of LON:OXB opened at GBX 499 on Friday. The company’s 50-day moving average price is GBX 509.34 and its two-hundred day moving average price is GBX 575.10. Oxford Biomedica has a one year low of GBX 420 and a one year high of GBX 952. The company has a debt-to-equity ratio of 273.08, a current ratio of 2.21 and a quick ratio of 1.67. The stock has a market capitalization of £604.03 million, a PE ratio of -18.54 and a beta of 1.09.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Jefferies Financial Group restated a “buy” rating and set a GBX 8.27 price objective on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a GBX 900 target price on shares of Oxford Biomedica in a report on Tuesday, September 1st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of GBX 580.85.

Insider Buying and Selling at Oxford Biomedica

In related news, insider Roch Doliveux acquired 20,250 shares of the company’s stock in a transaction dated Wednesday, September 23rd. The shares were bought at an average price of GBX 505 per share, for a total transaction of £102,262.50. 43.30% of the stock is owned by company insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.